<?xml version="1.0"?>
<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.4 20190208//EN"
       "JATS-journalpublishing1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="1.4" xml:lang="en">
 <front>
  <journal-meta>
   <journal-id journal-id-type="publisher-id">Medical Radiology and radiation safety</journal-id>
   <journal-title-group>
    <journal-title xml:lang="en">Medical Radiology and radiation safety</journal-title>
    <trans-title-group xml:lang="ru">
     <trans-title>Медицинская радиология и радиационная безопасность</trans-title>
    </trans-title-group>
   </journal-title-group>
   <issn publication-format="print">1024-6177</issn>
   <issn publication-format="online">2618-9615</issn>
  </journal-meta>
  <article-meta>
   <article-id pub-id-type="publisher-id">29420</article-id>
   <article-id pub-id-type="doi">10.12737/article_5d110f04375033.57581297</article-id>
   <article-categories>
    <subj-group subj-group-type="toc-heading" xml:lang="ru">
     <subject>Ядерная медицина</subject>
    </subj-group>
    <subj-group subj-group-type="toc-heading" xml:lang="en">
     <subject>Nuclear medicine</subject>
    </subj-group>
    <subj-group>
     <subject>Ядерная медицина</subject>
    </subj-group>
   </article-categories>
   <title-group>
    <article-title xml:lang="en">Leakage Radiometric Control of Chemical Drugs with Regional Perfusion of Surgical Isolated Limbs</article-title>
    <trans-title-group xml:lang="ru">
     <trans-title>Радиометрический контроль утечки химиопрепарата при регионарной перфузии хирургически изолированной конечности</trans-title>
    </trans-title-group>
   </title-group>
   <contrib-group content-type="authors">
    <contrib contrib-type="author">
     <name-alternatives>
      <name xml:lang="ru">
       <surname>Наркевич</surname>
       <given-names>Борис Ярославович</given-names>
      </name>
      <name xml:lang="en">
       <surname>Narkevich</surname>
       <given-names>Boris Yaroslavovich</given-names>
      </name>
     </name-alternatives>
     <email>medradiol@yandex.ru</email>
     <bio xml:lang="ru">
      <p>доктор технических наук;</p>
     </bio>
     <bio xml:lang="en">
      <p>doctor of technical sciences;</p>
     </bio>
     <xref ref-type="aff" rid="aff-1"/>
     <xref ref-type="aff" rid="aff-2"/>
    </contrib>
    <contrib contrib-type="author">
     <name-alternatives>
      <name xml:lang="ru">
       <surname>Ширяев</surname>
       <given-names>С. В.</given-names>
      </name>
      <name xml:lang="en">
       <surname>Shiryaev</surname>
       <given-names>S. V.</given-names>
      </name>
     </name-alternatives>
     <bio xml:lang="ru">
      <p>доктор медицинских наук;</p>
     </bio>
     <bio xml:lang="en">
      <p>doctor of medical sciences;</p>
     </bio>
     <xref ref-type="aff" rid="aff-3"/>
    </contrib>
    <contrib contrib-type="author">
     <name-alternatives>
      <name xml:lang="ru">
       <surname>Лагутина</surname>
       <given-names>И. В.</given-names>
      </name>
      <name xml:lang="en">
       <surname>Lagutina</surname>
       <given-names>I. V.</given-names>
      </name>
     </name-alternatives>
     <xref ref-type="aff" rid="aff-4"/>
     <xref ref-type="aff" rid="aff-5"/>
    </contrib>
    <contrib contrib-type="author">
     <name-alternatives>
      <name xml:lang="ru">
       <surname>Буйденок</surname>
       <given-names>Ю. В.</given-names>
      </name>
      <name xml:lang="en">
       <surname>Buydenok</surname>
       <given-names>Yu. V.</given-names>
      </name>
     </name-alternatives>
     <bio xml:lang="ru">
      <p>доктор медицинских наук;</p>
     </bio>
     <bio xml:lang="en">
      <p>doctor of medical sciences;</p>
     </bio>
     <xref ref-type="aff" rid="aff-6"/>
    </contrib>
    <contrib contrib-type="author">
     <name-alternatives>
      <name xml:lang="ru">
       <surname>Харатишвили</surname>
       <given-names>Т. К.</given-names>
      </name>
      <name xml:lang="en">
       <surname>Kharatishvili</surname>
       <given-names>T. K.</given-names>
      </name>
     </name-alternatives>
     <bio xml:lang="ru">
      <p>доктор медицинских наук;</p>
     </bio>
     <bio xml:lang="en">
      <p>doctor of medical sciences;</p>
     </bio>
     <xref ref-type="aff" rid="aff-7"/>
    </contrib>
    <contrib contrib-type="author">
     <name-alternatives>
      <name xml:lang="ru">
       <surname>Петроченко</surname>
       <given-names>Н. С.</given-names>
      </name>
      <name xml:lang="en">
       <surname>Petrochenko</surname>
       <given-names>N. S.</given-names>
      </name>
     </name-alternatives>
     <bio xml:lang="ru">
      <p>кандидат медицинских наук;</p>
     </bio>
     <bio xml:lang="en">
      <p>candidate of medical sciences;</p>
     </bio>
     <xref ref-type="aff" rid="aff-8"/>
    </contrib>
   </contrib-group>
   <aff-alternatives id="aff-1">
    <aff>
     <institution xml:lang="ru">Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина Минздрава РФ</institution>
     <city>Москва</city>
     <country>Россия</country>
    </aff>
    <aff>
     <institution xml:lang="en">N.N. Blokhin National Medical Research Center of Oncology</institution>
     <city>Moscow</city>
     <country>Russian Federation</country>
    </aff>
   </aff-alternatives>
   <aff-alternatives id="aff-2">
    <aff>
     <institution xml:lang="ru">Ассоциация медицинских физиков России</institution>
     <city>Москва</city>
     <country>Россия</country>
    </aff>
    <aff>
     <institution xml:lang="en">Association of Medical Physicists of Russia</institution>
     <city>Moscow</city>
     <country>Russian Federation</country>
    </aff>
   </aff-alternatives>
   <aff-alternatives id="aff-3">
    <aff>
     <institution xml:lang="ru">Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина Минздрава России</institution>
     <city>Москва</city>
     <country>Россия</country>
    </aff>
    <aff>
     <institution xml:lang="en">N.N. Blokhin National Medical Research Center of Oncology</institution>
     <city>Moscow</city>
     <country>Russian Federation</country>
    </aff>
   </aff-alternatives>
   <aff-alternatives id="aff-4">
    <aff>
     <institution xml:lang="ru">Ассоциация медицинских физиков России</institution>
     <city>Москва</city>
     <country>Россия</country>
    </aff>
    <aff>
     <institution xml:lang="en">Association of Medical Physicists of Russia</institution>
     <city>Moscow</city>
     <country>Russian Federation</country>
    </aff>
   </aff-alternatives>
   <aff-alternatives id="aff-5">
    <aff>
     <institution xml:lang="ru">Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина Минздрава РФ</institution>
     <city>Москва</city>
     <country>Россия</country>
    </aff>
    <aff>
     <institution xml:lang="en">N.N. Blokhin National Medical Research Center of Oncology</institution>
     <city>Moscow</city>
     <country>Russian Federation</country>
    </aff>
   </aff-alternatives>
   <aff-alternatives id="aff-6">
    <aff>
     <institution xml:lang="ru">Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина Минздрава РФ</institution>
     <city>Москва</city>
     <country>Россия</country>
    </aff>
    <aff>
     <institution xml:lang="en">N.N. Blokhin National Medical Research Center of Oncology</institution>
     <city>Moscow</city>
     <country>Russian Federation</country>
    </aff>
   </aff-alternatives>
   <aff-alternatives id="aff-7">
    <aff>
     <institution xml:lang="ru">Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина Минздрава РФ</institution>
     <city>Москва</city>
     <country>Россия</country>
    </aff>
    <aff>
     <institution xml:lang="en">N.N. Blokhin National Medical Research Center of Oncology</institution>
     <city>Moscow</city>
     <country>Russian Federation</country>
    </aff>
   </aff-alternatives>
   <aff-alternatives id="aff-8">
    <aff>
     <institution xml:lang="ru">Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина Минздрава РФ</institution>
     <city>Москва</city>
     <country>Россия</country>
    </aff>
    <aff>
     <institution xml:lang="en">N.N. Blokhin National Medical Research Center of Oncology</institution>
     <city>Moscow</city>
     <country>Russian Federation</country>
    </aff>
   </aff-alternatives>
   <volume>64</volume>
   <issue>4</issue>
   <fpage>48</fpage>
   <lpage>55</lpage>
   <self-uri xlink:href="https://zh-szf.ru/en/nauka/article/29420/view">https://zh-szf.ru/en/nauka/article/29420/view</self-uri>
   <abstract xml:lang="ru">
    <p>Цель: Модернизация и оценка клинической эффективности технологии непрерывного радиометрического контроля, проводимого при высокодозной химиотерапии хирургически изолированной конечности с опухолевыми очагами.&#13;
Материал и методы: Предложена модернизированная технология радиометрического контроля регионарной перфузии конечности. Она основана на in vivo мечении эритроцитов элюатом 99mTc с последующим непрерывным мониторингом активности меченых эритроцитов как имитатора химиопрепарата над областью сердца. Ее отличительными особенностями является внутривенное введение пирфотеха срезу после дачи ингаляционного наркоза с целью обеспечения достаточного уровня хелатирования эритроцитов, а также использование активности 99mTc менее ее минимально допустимого уровня, что позволяет проводить работы с открытым источником ионизирующего излучения без нарушения требований нормативных документов по обеспечению радиационной безопасности. &#13;
Результаты: Разработанная технология была успешно использована при 106 регионарных перфузиях верхних и нижних конечностей у больных меланомой или саркомой мягких тканей. В 4 случаях по результатам радиометрического контроля понадобилось вмешательство хирургической бригады для уменьшения происходящей утечки химиопрепарата. &#13;
Заключение: Модернизированная нами технология непрерывного радиометрического мониторинга in vivo меченных 99mTc эритроцитов отличается простотой выполнения, клинической эффективностью за счет своевременного принятия мер по предотвращению или снижению утечки химиопрепарата из изолированной конечности, выполнением радиационно-гигиенических требований по работе с открытыми источниками ионизирующих излучений непосредственно в хирургической операционной, а также низкой лучевой нагрузкой на больного и персонал.</p>
   </abstract>
   <trans-abstract xml:lang="en">
    <p>Purpose: Modernization and evaluation of the clinical effectiveness of the technology of continuous radiometric monitoring carried out during high-dose chemotherapy of a surgically isolated limb with tumor foci.&#13;
Material and methods: A modernized radiometric control technology for regional limb perfusion is proposed. It is based on in vivo labeling of erythrocytes with 99mTc eluate followed by continuous monitoring of the activity of labeled erythrocytes as a simulator of a chemotherapy drug over the heart region. Its distinctive features are intravenous injection of a pyrfotech slice after giving inhalation anesthesia to ensure a sufficient level of red blood cell chelation, as well as using 99mTc activity less than its minimum significant level, which allows working with an open source of ionizing radiation without violating the requirements of radiation safety regulations.&#13;
Results: The developed technology was successfully used with 106 regional perfusion of the upper and lower extremities in patients with melanoma or sarcoma of soft tissues. In 4 cases, according to the results of radiometric control, the intervention of the surgical team was required to reduce the chemical preparation leakage that was occurring.&#13;
Conclusion: The technology upgraded by us is characterized by ease of implementation, the ability to take timely measures to prevent or reduce the leakage of a chemotherapy drug from an isolated limb according to the results of continuous in vivo radiometric monitoring of 99mTc-labeled red blood cells over the heart, as well as low radiation load on the patient and staff.</p>
   </trans-abstract>
   <kwd-group xml:lang="ru">
    <kwd>высокодозная химиотерапия</kwd>
    <kwd>хирургически изолированная конечность</kwd>
    <kwd>регионарная перфузия</kwd>
    <kwd>утечка химиопрепарата</kwd>
    <kwd>радиометрический контроль</kwd>
   </kwd-group>
   <kwd-group xml:lang="en">
    <kwd>high-dose chemotherapy</kwd>
    <kwd>surgically isolated limb</kwd>
    <kwd>regional perfusion</kwd>
    <kwd>chemotherapy leaks</kwd>
    <kwd>radiometric monitoring</kwd>
   </kwd-group>
  </article-meta>
 </front>
 <body>
  <p>ВведениеСреди пациентов, страдающих такими заболеваниями, как меланома кожи, рак кожи и саркомы мягких тканей, выделяют группу с местно-распространенными формами опухолевого процесса. Стандартные методы лечения пораженных конечностей, включающие хирургическое лечение, химио- и лучевую терапию, не всегда оказываются эффективными. Особенности течения болезни иногда не позволяют использовать сохранные оперативные вмешательства, а калечащие операции, например ампутация пораженной конечности, резко снижают качество жизни пациентов. В некоторых случаях тот или иной метод лечения из указанных выше не может быть использован вообще.  </p>
 </body>
 <back>
  <ref-list>
   <ref id="B1">
    <label>1.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Clinical recommendations. Cervical cancer. The association of Russian oncologists. 2017. ID: KP537 [cited 2018 Dec 27] Available from: http://cancerlink.ru/cancer/clinical-guidelines-oncology-2017/clinical-guidelines-aor-2017 . (Russian).</mixed-citation>
     <mixed-citation xml:lang="en">Clinical recommendations. Cervical cancer. The association of Russian oncologists. 2017. ID: KP537 [cited 2018 Dec 27] Available from: http://cancerlink.ru/cancer/clinical-guidelines-oncology-2017/clinical-guidelines-aor-2017 . (Russian).</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B2">
    <label>2.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">NCCN (National Comprehensive Cancer Network, OCT 2017) (version 1.2019) Available at nccn.org. [cited 2018 Nov 05]</mixed-citation>
     <mixed-citation xml:lang="en">NCCN (National Comprehensive Cancer Network, OCT 2017) (version 1.2019) Available at nccn.org. [cited 2018 Nov 05]</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B3">
    <label>3.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">TNM classification of malignant tumours. Sobin LH, Gospodarowicz MK, Wittekind C, eds. 7th ed. NY: Springer-Verlag, 2010. 256 p.</mixed-citation>
     <mixed-citation xml:lang="en">TNM classification of malignant tumours. Sobin LH, Gospodarowicz MK, Wittekind C, eds. 7th ed. NY: Springer-Verlag, 2010. 256 p.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B4">
    <label>4.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Kaprin AD, Titova VA, Kostin AA, Rerberg AG. Improving the Diagnosis and Treatment of Retention Disorders of the Upper Urinary Tract in Patients with Stages IIB-III cancer of the Cervix Uteri. Cancer Urology. 2012;8(2):98-101. DOI: 10.17650/1726-9776-2012-8-2-98-101. (Russian).</mixed-citation>
     <mixed-citation xml:lang="en">Kaprin AD, Titova VA, Kostin AA, Rerberg AG. Improving the Diagnosis and Treatment of Retention Disorders of the Upper Urinary Tract in Patients with Stages IIB-III cancer of the Cervix Uteri. Cancer Urology. 2012;8(2):98-101. DOI: 10.17650/1726-9776-2012-8-2-98-101. (Russian).</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B5">
    <label>5.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Rose PG, Ali S, Whitney CW, Lanciano R, Stehman FB. Impact of hydronephrosis on outcome of stage IIIB cervical cancer patients with disease limited to the pelvis, treated with radiation and concurrent chemotherapy: A Gynecologic Oncology Group study. Gynecol. Oncol. 2010; 117(2):270-5. DOI: 10.1016/j.ygyno.2010.01.045.</mixed-citation>
     <mixed-citation xml:lang="en">Rose PG, Ali S, Whitney CW, Lanciano R, Stehman FB. Impact of hydronephrosis on outcome of stage IIIB cervical cancer patients with disease limited to the pelvis, treated with radiation and concurrent chemotherapy: A Gynecologic Oncology Group study. Gynecol. Oncol. 2010; 117(2):270-5. DOI: 10.1016/j.ygyno.2010.01.045.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B6">
    <label>6.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Goklu MR, Seckin KD, Togrul C, Goklu Y, Tahaoglu AE, Oz M, et al. Effect of hydronephrosis on survival in advanced stage cervical cancer. Asian Pac J Cancer Prev. 2015;16(10):4219-22. DOI:10.7314/APJCP.2015.16.10.4219</mixed-citation>
     <mixed-citation xml:lang="en">Goklu MR, Seckin KD, Togrul C, Goklu Y, Tahaoglu AE, Oz M, et al. Effect of hydronephrosis on survival in advanced stage cervical cancer. Asian Pac J Cancer Prev. 2015;16(10):4219-22. DOI:10.7314/APJCP.2015.16.10.4219</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B7">
    <label>7.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Beckta JM, Carter JS, Wan W, Chafe WE, Abayomi OK, Proper MA, et al. Urinary Diversion in the Management of Locally Advanced Cervical Cancer Facilitates the Use of Aggressive Therapy without Adversely Effecting Overall Treatment Time. EC Gynaecology. 2016;3(1): 225-31.</mixed-citation>
     <mixed-citation xml:lang="en">Beckta JM, Carter JS, Wan W, Chafe WE, Abayomi OK, Proper MA, et al. Urinary Diversion in the Management of Locally Advanced Cervical Cancer Facilitates the Use of Aggressive Therapy without Adversely Effecting Overall Treatment Time. EC Gynaecology. 2016;3(1): 225-31.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B8">
    <label>8.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Mankad M, Mishra K, Desai A, Patel S. Role of percutaneous nephrostomy in advanced cervical carcinoma with obstructive uropathy: a case series. Indian J Palliat Care. 2009;15(1):37-40.</mixed-citation>
     <mixed-citation xml:lang="en">Mankad M, Mishra K, Desai A, Patel S. Role of percutaneous nephrostomy in advanced cervical carcinoma with obstructive uropathy: a case series. Indian J Palliat Care. 2009;15(1):37-40.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B9">
    <label>9.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Chepurov AK, Zenkov SS, Mamaev NE, Pronkin EA. Prolonged drainage by ureteral stents: current state of the issue and prospects. Andrology and Genital Surgery. 2009;(2):44-8. (Russian).</mixed-citation>
     <mixed-citation xml:lang="en">Chepurov AK, Zenkov SS, Mamaev NE, Pronkin EA. Prolonged drainage by ureteral stents: current state of the issue and prospects. Andrology and Genital Surgery. 2009;(2):44-8. (Russian).</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B10">
    <label>10.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Pecorelli S. Revised FIGO staging for carcinoma of vulva, cervix, and endometrium. Int J Gynec Obstet. 2009;(105):103-4.</mixed-citation>
     <mixed-citation xml:lang="en">Pecorelli S. Revised FIGO staging for carcinoma of vulva, cervix, and endometrium. Int J Gynec Obstet. 2009;(105):103-4.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B11">
    <label>11.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Kaprin AD, Titova VA, Kreynina YuM, Kostin AA. Urological complications in oncologic practice: diagnosis, interventional and conservative correction. Moscow; 2011. 168 p. (Russian).</mixed-citation>
     <mixed-citation xml:lang="en">Kaprin AD, Titova VA, Kreynina YuM, Kostin AA. Urological complications in oncologic practice: diagnosis, interventional and conservative correction. Moscow; 2011. 168 p. (Russian).</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B12">
    <label>12.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Protein-energy deficiency in cancer. In: Baranovsky AYu, editor. Dietetics: Manual 5th edition. St. Petersburg: Piter; 2017. p. 868-74. (Russian).</mixed-citation>
     <mixed-citation xml:lang="en">Protein-energy deficiency in cancer. In: Baranovsky AYu, editor. Dietetics: Manual 5th edition. St. Petersburg: Piter; 2017. p. 868-74. (Russian).</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B13">
    <label>13.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Kurpeshev OK, Mardynsky YuS. Basic principles and methods of radiomodification in radiotherapy. In: Kaprin AD, Mardynsky YuS, editors. Therapeutic Radiology. National leadership. Moscow: GEOTAR-Media; 2018. P. 89-128. (Russian).</mixed-citation>
     <mixed-citation xml:lang="en">Kurpeshev OK, Mardynsky YuS. Basic principles and methods of radiomodification in radiotherapy. In: Kaprin AD, Mardynsky YuS, editors. Therapeutic Radiology. National leadership. Moscow: GEOTAR-Media; 2018. P. 89-128. (Russian).</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B14">
    <label>14.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Brotherhood H, Lange D, Chew BH. Advances in ureteral stents. Transl Androl Urol 2014;3(3):314-9. DOI: 10.3978/j.issn.2223-4683.2014.06.06.</mixed-citation>
     <mixed-citation xml:lang="en">Brotherhood H, Lange D, Chew BH. Advances in ureteral stents. Transl Androl Urol 2014;3(3):314-9. DOI: 10.3978/j.issn.2223-4683.2014.06.06.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B15">
    <label>15.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Boyko AV, Korytova LI, Oltarzhevskaya ND, editors. Targeted drug delivery in the treatment of cancer patients. Moscow: Special Medical Book Publisher; 2013. p. 200. (Russian).</mixed-citation>
     <mixed-citation xml:lang="en">Boyko AV, Korytova LI, Oltarzhevskaya ND, editors. Targeted drug delivery in the treatment of cancer patients. Moscow: Special Medical Book Publisher; 2013. p. 200. (Russian).</mixed-citation>
    </citation-alternatives>
   </ref>
  </ref-list>
 </back>
</article>
